BRAIN

Preferred Sample Type

Paraneoplastic Antibodies (Hu, Yo, Ri)

Suitable Specimen Types

  • Serum
Min 2.0ml serum

Sample Processing in Laboratory

Sample Preparation

Turnaround Time

7 days

Sample Stability

4oC

Paraneoplastic Antibodies (Hu, Yo, Ri)

General Information

Paraneoplastic antibodies are associated with a variety of neurological manifestations that are also associated with, and may be reactive with, an underlying malignancy. The demonstration of these antibodies may initiate a search for covert malignancy. In some cases tumour elimination may result in the reduction in antibody levels and the amelerioration of associated syndromes. Anti-Yo (PCA1) antibodies; associated tumour = Breast and ovarian carcinomas (Anti-Yo antibodies are usually only found in female patients); neurological syndrome = Cerebellar degeneration. Anti-Hu (ANNA1) antibodies; associated tumour = small cell lung carcinoma and neuroblastoma; neurological syndrome = cerebellar ataxia, paraneoplastic encephalomyelitis/sensory neuropathy. Anti-Ri (ANNA2) antibodies; associated tumour = breast, small cell lung carcinoma, gynaecological; neurological syndrome = opsoclonus/myclonus, paraneoplastic cerebellar degeneration, brainstem encephalomyelitis.

Notes

Follow-up tests on positives also weekly, these are performed at a referral laboratory

Reference Range

Negative

Specifications

  • EQA Scheme?: Yes
  • EQA Status:

    Participate in pilot EQA scheme run by UKNEQAS

Copyright heftpathology 2013, 2014, 2015, 2016, 2017, 2018

HTA licence number is 12366

Protection of Personal Information – Laboratory Medicine comply with the Trust Data Protection Policy and have procedures in place to allow the Directorate and it’s employees to comply with the Data Protection Act 1998 and associated best practice and guidance.

The Trust Laboratories at Heartlands Hospital, Good Hope Hospital and Solihull Hospital were awarded UKAS (United Kingdom Accreditation Service) accreditation to the internationally recognised ISO 15189 standard in May 2015. For a list of accredited tests and other information please visit the test database http://www.heftpathology.com/frontpage/test-database.html.
Tests not appearing on this scope are either under consideration or in the process of accreditation and so currently remain outside of our scope of accreditation. However, these tests have been validated to the same high standard as accredited tests and are performed by the same trained and competent staff.

For further information contact Louise Fallon, Quality Manager, 0121 424 1235

UKAS HEFT